Become Affiliate

PepFlow

Download

The NAD Precursor

Nicotinamide Riboside (NR)

Nicotinamide riboside is an NAD+ precursor with controlled oral human studies and a separate investigational NR-chloride vial protocol.

NAD+ aging biologyMetabolic health
TierB
EvidenceModerate
SafetyLimited Data
FDA statusNot Approved
Last reviewed October 25, 2026 35 citations How to read these labels

What is Nicotinamide Riboside (NR)?

Nicotinamide riboside is a vitamin B3-related NAD+ precursor distinct from NMN and direct NAD+.[1][2][3]

The oral and injectable routes use separate evidence: controlled oral trials support daily capsules, while the vial schedule remains investigational and product-specific.[1][2][3]

What Nicotinamide Riboside (NR) is investigated for

Nicotinamide Riboside (NR) evidence is grouped by practical use case and oral, injectable, and topical route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

Oral NAD+ biomarker support

Oral

74%Moderate

Oral NAD+ biomarker restoration is the most reproducible NR finding; it should not be treated as proof of symptom, disease, or longevity benefit.[1][12][13]

Human evidence

Randomized studies show reproducible, dose-responsive increases in whole-blood NAD+ and related metabolites, with evidence extending to cerebral and skeletal-muscle NAD biology.[1][2][3][17][10]

Animal / mechanistic evidence

Animal and biochemical work established the precursor rationale, but the confidence score here is driven by controlled human biomarker studies.[26][24][25]

Walking performance in peripheral artery disease

Oral

60%Emerging

The walking signal is promising but condition-specific and needs larger independent confirmation before routine clinical claims.[7][13]

Human evidence

The NICE randomized clinical trial in peripheral artery disease reported a modest improvement in six-minute walk distance after six months, with a stronger exploratory signal in a combination arm.[7]

Animal / mechanistic evidence

Preclinical vascular and mitochondrial rationale exists, but the clinical confidence rests on one condition-specific trial.[26][12]

Neurocognitive support

Oral

52%Emerging

NR is an active research strategy for neurologic conditions, not an established cognitive enhancer or neurodegenerative treatment.[5][6][23]

Human evidence

Trials in mild cognitive impairment, subjective cognitive decline, and Parkinson's disease show blood or neurodegeneration-biomarker changes, but cognitive and disease-modifying outcomes remain inconsistent or unproven.[20][5][6][23]

Animal / mechanistic evidence

Extensive neuroprotective rationale exists in model systems, but it does not resolve the mixed human clinical findings.[26][12]

Cardiometabolic health

Oral

44%Preliminary

Cardiometabolic use remains exploratory and should not be represented as a proven glucose, lipid, blood-pressure, or weight-loss intervention.[18][15][14]

Human evidence

Studies report some exploratory vascular signals, but multiple controlled trials found no meaningful improvement in insulin sensitivity, lipids, mitochondrial respiration, or broad body composition.[2][18][15][14][22]

Animal / mechanistic evidence

Preclinical metabolic benefits are stronger and more consistent than the human outcome evidence.[26][12]

Healthy aging and longevity

Oral

16%Insufficient

NR should be described as a studied NAD+ precursor, not a proven anti-aging or lifespan-extending treatment.[12][13]

Human evidence

Human trials demonstrate NAD+ biomarker engagement but not lifespan extension or broad prevention of age-related disease.[12][13]

Animal / mechanistic evidence

Aging-pathway and animal evidence motivates human study but cannot establish a human longevity effect.[26][12]

Evidence snapshot

70%

Human evidence

Moderate

Human data are strongest for oral NR; injection evidence is early and protocol-focused.[1][2][3][28]

28%

Animal / preclinical

Limited

The approved defaults rely on route-matched human or protocol sources rather than animal dose extrapolation.[1][2][3]

72%

Mechanism support

Moderate

NR enters NAD+ biosynthesis through nicotinamide riboside kinase pathways.[1][2][3]

Forms & administration

NR has oral supplement and NR-chloride vial presentations. Topical gels remain experimental, with animal-only evidence. Each form has distinct concentration and delivery requirements; topical preparations cannot inherit the amounts, absorption or treatment expectations associated with oral supplements or injectable products.[1][2][3][28][32][31]

OralInjectableTopical

Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

Typical Range

Oral protocols commonly use 300 mg per day. Injectable research protocols use 50 mg per dose.[1][2][3][28][32]

Frequency

Oral NR is taken once daily. Injection schedules use daily doses for 3 days, then 3 doses weekly.[1][28]

Cycle Length

Oral protocols may run 8 weeks. Injectable research schedules may continue to day 100.[1][28]

What to expect

First 1–2 weeks

Blood NAD+ and related metabolites can rise early, but a biomarker response does not predict a noticeable clinical effect.[19][1]

Weeks 4–8

Most short trials reassess NAD+ biomarkers, tolerability, and condition-specific exploratory outcomes in this window; many metabolic and cognitive outcomes remain unchanged.[1][5][6]

Months 3–6

Longer condition-specific trials may be needed for functional outcomes; the PAD walking signal was measured over six months and should not be generalized to healthy users.[7]

After stopping

NAD-related biomarker gains are not expected to represent a permanent change, but exact washout timing and symptom durability are not consistently mapped across trials.[2][12]

Safety profile

Oral NR has controlled human tolerability data across several short trials, including a high-dose Parkinson's safety study, without a consistent excess pattern of serious adverse events. Long-term and injectable safety remain less certain.[1][2][4][33]

Cautions

What we don't know

Multi-year use, pregnancy, pediatric use, and injectable safety remain incompletely characterized.[12][13][28]

Who Nicotinamide Riboside (NR) is not for

Route-specific avoid and medical-review notes:

  • Pregnancy or breastfeeding without clinician review

    Pregnancy and breastfeeding safety data are insufficient for the reviewed oral and investigational injectable use.[12][13]

How it works

Oral NR is absorbed and metabolized through pathways that can raise circulating NAD-related metabolites. Controlled studies demonstrate biomarker changes across several daily doses.[1][2][3]

Injectable NR chloride bypasses oral delivery but remains an investigational route. Its preparation and cadence come from a specific human safety protocol rather than from direct NAD+ practice.[1][2][3][28]

Research gaps & open questions

What the current literature has not yet settled about Nicotinamide Riboside (NR):

01

Injectable NR needs larger placebo-controlled studies that measure safety, blood levels, tissue exposure, and clinical outcomes.[1][2][3]

02

Long-term clinical outcomes need independent testing that goes beyond changes in NAD-related blood biomarkers.[1][2][3]

03

The peripheral-artery-disease walking signal needs larger replication and clarity on which patients, co-interventions, and outcomes are most responsive.[7][13]

04

Neurologic trials need clearly chosen clinical outcomes and enough duration to distinguish biomarker movement from cognitive or disease-modifying benefit.[5][6][23]

05

Research should define long-term safety and clinically meaningful outcomes in older adults, chronic-disease populations, and people taking multiple medications.[12][13]

Common questions

Is NR direct NAD+?

No. NR is a precursor that can be converted through NAD+ biosynthetic pathways.[1][2][3]

Why does the vial use NR chloride as the medication name?

The canonical molecule is nicotinamide riboside, so the sourced commercial kit remains searchable and in provenance rather than replacing the medication identity.[28][32]

Does NR have proven anti-aging or longevity benefits?

No human trial has shown lifespan extension. NR reliably raises NAD-related biomarkers, but clinical outcome results are mixed and condition-specific.[12][13]

Does NR improve memory or treat neurodegenerative disease?

Not established. Trials report some NAD-related or disease-biomarker changes, but cognitive and disease-modifying benefit has not been consistently demonstrated.[5][6][23]

Does oral NR evidence validate injectable NR?

No. Oral trials cannot establish the pharmacokinetics, sterility, safety, or clinical outcomes of an injectable NR-chloride product; the injectable route remains investigational.[1][28][33]

Myths & misconceptions

Myth

An NR vial is a generic NAD+ vial.

Reality

NR chloride and direct NAD+ are different molecules with separate dose and preparation records.[1][2][3][28]

Myth

A higher blood NAD+ result proves that NR is improving health.

Reality

Blood NAD+ is a target-engagement biomarker. Multiple trials raised NAD-related measures without improving the main metabolic, muscle, or cognitive outcomes studied.[18][15][5]

Myth

Food or supplement availability means NR is an FDA-approved drug.

Reality

No. Food/supplement status, a GRAS notice response, and FDA drug approval are different regulatory pathways.[29][33]

History & discovery

Nicotinamide riboside is a vitamin B3 form and NAD+ precursor. Human development progressed from oral bioavailability and pharmacokinetic studies to randomized trials across healthy aging, metabolic, neurologic, vascular, and mobility contexts. Across that history, NAD+ biomarker engagement has been more reproducible than clinical benefit.[27][19][12][13]

NR was contextualized alongside nicotinic acid and nicotinamide as a human NAD+ precursor vitamin.[27]

Human studies established oral bioavailability, blood NAD+ increases, and short-term tolerability across controlled exposure ranges.[25][2][1]

Trials expanded into neurologic, vascular, pulmonary, muscle, and mobility outcomes, with mixed clinical results despite biomarker engagement.[20][7][21][23]

Published research35 citations

Show citationsHide citations

PepFlow library coverage

Keep It Organized

Build consistency around your healthy-aging goals.

Use PepFlow to record your Nicotinamide Riboside (NR) protocol, set reminders for your own schedule, and review your history.

Download on the App StoreGet it on Google Play
PepFlow calendar on Thursday, April 9, listing BPC-157 at 10:00 and GHK-CU at 18:00